AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
IPO Year: 2004
Exchange: NASDAQ
Website: angiodynamics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | $12.00 | Perform → Outperform | Oppenheimer |
| 9/25/2023 | $19.00 | Buy | H.C. Wainwright |
| 4/17/2023 | $14.00 → $13.00 | Strong Buy → Outperform | Raymond James |
| 10/15/2021 | $28.00 → $37.00 | Hold → Buy | Canaccord Genuity |
| 8/20/2021 | Perform | Oppenheimer | |
| 7/14/2021 | $24.00 → $28.00 | Hold | Canaccord Genuity |
| 7/9/2021 | $27.00 → $32.00 | Strong Buy | Raymond James |
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $72.0 million 9.2% Med Tech Net Sales $31.3 million 22.2% Med Device Net Sales $40.7 million 0.9% GAAP gross margin of 54.0% GAAP loss per share of $(0.11) Adjusted loss per shar
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference at 12:00 p.m. ET on Monday, March 17, 2025. A live webcast of the presentation will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for repl
Trial Evaluates Effectiveness of Innovative Auryon Atherectomy System in Complex Below-the-Knee Cases AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK). AMBITION BTK is a multicenter, randomized controlled trial (RCT) designed to
Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment. AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thro
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $73.0 million 9.2% Med Tech Net Sales $31.5 million 25.0% Med Device Net Sales $41.5 million (0.4)% GAAP Gross margin of 54.8% GAAP loss pe
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PT on Thursday, January 16, 2025. A live webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event.
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual NanoKnife System Event Date: Wednesday, January 8, 2025 Time: 9:30am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-85
SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
3 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
SCHEDULE 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
SCHEDULE 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SCHEDULE 13G - ANGIODYNAMICS INC (0001275187) (Subject)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00
H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00
Raymond James downgraded AngioDynamics from Strong Buy to Outperform and set a new price target of $13.00 from $14.00 previously
Canaccord Genuity upgraded AngioDynamics from Hold to Buy and set a new price target of $37.00 from $28.00 previously
Oppenheimer initiated coverage of AngioDynamics with a rating of Perform
Canaccord Genuity reiterated coverage of AngioDynamics with a rating of Hold and set a new price target of $28.00 from $24.00 previously
Raymond James reiterated coverage of AngioDynamics with a rating of Strong Buy and set a new price target of $32.00 from $27.00 previously
Canaccord Genuity reiterated coverage of AngioDynamics with a rating of Hold and set a new price target of $24.00 from $18.00 previously
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sales $72.0 million 9.2% Med Tech Net Sales $31.3 million 22.2% Med Device Net Sales $40.7 million 0.9% GAAP gross margin of 54.0% GAAP loss per share of $(0.11) Adjusted loss per shar
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual Cardiovascular Investor Event Date: Wednesday, April 2, 2025 Time: 9:00am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=c
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products. Fiscal 2025 Third Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $73.0 million 9.2% Med Tech Net Sales $31.5 million 25.0% Med Device Net Sales $41.5 million (0.4)% GAAP Gross margin of 54.8% GAAP loss pe
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Conference Call which will start at 8:00am ET the same day. Virtual NanoKnife System Event Date: Wednesday, January 8, 2025 Time: 9:30am ET Duration: 60 minutes Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarter Financial Results Conference Call The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-85
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million 1.1% Med Tech Net Sales $28.0 million 8.7% Med Device Net Sales $39.5 million (3.6)% GAAP gross margin of 54.4% GAAP loss per share of $0.31 Adjusted loss per share of $0.11 Sub
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angi
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024. Fiscal Year 2024 Fourth Quarter Highlights Quarter Ended May 31, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $71.1 million 1.9% Med Tech Net Sales $29.3 million 11.3% Med Device Net Sales $41.8 million (3.8)% GAAP Gross margin of 54.3% GAAP loss per sh
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2024 before the market open on Tuesday, July 16, 2024. The Company's management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the A
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Richard C. Rosenzweig as Senior Vice President, General Counsel, effective January 31, 2021. Mr. Rosenzweig will also serve as Corporate Secretary to the AngioDynamics Board of Directors. Mr. Rosenzweig succeeds Stephen Trowbridge who has served as Executive Vice President, Chief Financial Officer, and General Counsel since February 2020. Mr. Trowbridge will continue in his role as Executive Vice President and Chief Financial Officer. AngioDynam